Survodutide Side Effects: What Studies Report

Survodutide in brief

Survodutide is an investigational once-weekly peptide that activates both the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. Reviews of dual and triple incretin-based agents grouped it with glucagon/GLP-1 co-agonists and described the pharmacological rationale of combining GLP-1-mediated appetite and glycaemic effects with glucagon-mediated effects on hepatic energy expenditure and lipid handling (PMID 40364529). A 2024 review of GLP-1, GIP/GLP-1 and GCGR/GLP-1 receptor agonists placed survodutide among agents studied for metabolic dysfunction-associated steatohepatitis (PMID 39735270).

Evidence tier: Established — the adverse-event information summarised on this page comes from randomised controlled trials in humans and from peer-reviewed reviews of those trials, not from cell or animal experiments. Where human data were absent in the verified literature, that absence is stated plainly rather than filled in.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medicine or symptom. This page does not describe how any compound is used.

Gastrointestinal Adverse Events: What Studies Report

Across the survodutide trials in the reference list, gastrointestinal events were the most frequently described adverse events. In a randomised, double-blind, placebo-controlled dose-finding phase 2 trial in people with obesity, participants received once-weekly survodutide at 0.6, 2.4, 3.6 or 4.8 mg or placebo for 46 weeks, and researchers reported that adverse events were predominantly gastrointestinal, including nausea, vomiting and constipation, and were more common with survodutide than with placebo (PMID 38330987).

In a phase 2 randomised trial in participants with MASH and fibrosis, survodutide was given once weekly at 2.4, 4.8 or 6.0 mg or placebo for 48 weeks, and the study reported that adverse events occurring more often with survodutide than placebo included nausea, diarrhoea and vomiting (PMID 38847460).

A 2026 report of once-weekly survodutide in adults with obesity likewise described gastrointestinal events as the principal tolerability issue alongside the trial's weight-related endpoints (PMID 42253238). A randomised trial in people with type 2 diabetes that compared several weekly survodutide doses with placebo and with open-label semaglutide reported that gastrointestinal events were the most common adverse events in the survodutide groups (PMID 38095657).

Why the pattern resembles the wider incretin class

A 2024 review of GLP-1 medicines for type 2 diabetes and obesity summarised class-level efficacy and safety, including gastrointestinal tolerability, and framed these events as an expected feature of GLP-1 receptor activation rather than a survodutide-specific finding (PMID 38843460). A 2025 systematic review of emerging obesity pharmacotherapies reached a similar characterisation when it grouped glucagon/GLP-1 dual agonists with other incretin-based agents under development (PMID 39952695).

Dose Escalation and Tolerability: What Studies Report

The obesity dose-finding trial was built to examine escalation itself: participants were assigned to rapid or slower escalation to target once-weekly doses of 0.6, 2.4, 3.6 or 4.8 mg over 46 weeks, and the study reported tolerability alongside the weight endpoints for each target dose (PMID 38330987). The MASH trial applied a comparable stepped approach toward once-weekly 2.4, 4.8 or 6.0 mg maintenance doses across 48 weeks and reported adverse events by assigned dose group (PMID 38847460).

Reviews of the broader class described escalation schedules as a standard design feature intended to limit gastrointestinal adverse events, and noted that reported event rates in trials were influenced by how quickly target doses were reached (PMID 38843460). This page does not describe schedules, quantities or administration for any individual; those decisions sit with prescribing clinicians.

Cardiovascular and Other Safety Signals: What Studies Report

Long-term cardiovascular outcome data for survodutide were not available in the verified literature. Investigators published the rationale and design of the SYNCHRONIZE cardiovascular outcomes trial, describing a trial intended to evaluate cardiovascular outcomes with survodutide in adults with obesity (PMID 39453356). Because that publication reported design rather than results, no cardiovascular event conclusions can be drawn from it.

A 2025 overview of weight-management treatment in obesity discussed incretin-based agents including glucagon/GLP-1 co-agonists within the context of clinical monitoring and treatment selection (PMID 40865172). A 2025 review of GLP-1 receptor agonists and glucagon/GIP/GLP-1 dual or triple agonists in MASLD similarly placed safety discussion within an emerging-evidence framing (PMID 40364529).

Cirrhosis and Hepatic Impairment: What Studies Report

One trial examined efficacy, tolerability and pharmacokinetics of survodutide specifically in people with cirrhosis, and researchers reported pharmacokinetic and tolerability findings in that population (PMID 38857788). Its existence matters for the safety literature because hepatic impairment can alter drug exposure, and the study was designed to characterise that question directly rather than infer it from trials in participants without cirrhosis (PMID 38857788).

Trial-by-Trial Snapshot

Survodutide Peptide Benefits: What Trials Measured

Questions about benefits and about adverse events are two sides of the same trial data, so the measured endpoints are summarised here rather than on a separate page. Nothing below is a prediction for any individual.

Body weight

The phase 2 dose-finding trial reported mean body-weight reductions that increased across the dose groups, reaching roughly 15% at the highest weekly dose after 46 weeks compared with about 3% with placebo (PMID 38330987). A 2026 trial of once-weekly survodutide in adults with obesity reported weight-related outcomes in a larger phase 3 setting (PMID 42253238). A 2025 Bayesian network meta-analysis compared GLP-1 receptor agonists, dual agonists and retatrutide for weight loss in adults with overweight or obesity, placing individual agents in a comparative ranking (PMID 40685589).

Glycaemic endpoints

In people with type 2 diabetes, the study reported dose-dependent reductions in HbA1c and bodyweight with survodutide compared with placebo, with open-label semaglutide included as a reference arm (PMID 38095657).

Liver endpoints

In the phase 2 MASH trial, researchers reported that biopsy-assessed improvement in MASH without worsening of fibrosis occurred in a substantially larger proportion of participants assigned survodutide than placebo across the 2.4, 4.8 and 6.0 mg weekly dose groups over 48 weeks (PMID 38847460). Reviews of incretin-based agents in MASH and MASLD described glucagon receptor co-agonism as a mechanistic reason liver endpoints were prioritised in this programme (PMID 39735270).

What the Cited Literature Does Not Establish

• Cardiovascular outcomes. The cited cardiovascular publication described trial rationale and design only, so no outcome results were reported there (PMID 39453356).
• Multi-year adverse-event rates. The verified trials described treatment periods of roughly 46 to 48 weeks in obesity and MASH (PMID 38330987, PMID 38847460), not multi-year follow-up.
• Pregnancy, breastfeeding and paediatric populations. No data in these groups appeared in the verified papers summarised here; that is an absence of evidence, not a safety reassurance.
• Head-to-head adverse-event comparisons. Indirect comparisons were modelled in a 2025 network meta-analysis rather than measured directly between agents (PMID 40685589).

Reading Adverse-Event Tables Critically

1. Placebo columns carry information. Nausea and constipation were also reported in placebo groups in the obesity dose-finding trial, which is why the study emphasised differences rather than raw frequencies (PMID 38330987).
2. Dose groups are not interchangeable. The MASH trial reported outcomes separately for 2.4, 4.8 and 6.0 mg weekly groups (PMID 38847460).
3. Population changes interpretation. Tolerability in participants with cirrhosis was studied in a dedicated trial rather than extrapolated (PMID 38857788).
4. Reviews summarise, they do not add data. Class reviews restated trial-level safety observations (PMID 38843460, PMID 39952695).

Regulatory and Naming Notes

Survodutide is an international nonproprietary (generic) name for a prescription-track investigational compound evaluated in sponsor-run clinical trials; the trials cited here were conducted under regulatory oversight in human participants. Any brand or product name associated with this molecule is a trademark of its owner, and PeptideU is not affiliated with or endorsed by any manufacturer, trial sponsor or trademark holder. PeptideU sells nothing and provides no sourcing information. Prescription-status and labelling questions belong with licensed clinicians and national regulators.

Related Learning

For a structured walk-through of dual glucagon/GLP-1 receptor pharmacology, trial design and endpoint definitions, the PeptideU course at /learn/survodutide/ teaches the mechanism and trial-reading skills; this page stays focused on what the published literature reported about adverse events, tolerability and measured endpoints.

References

• Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (The Lancet Diabetes & Endocrinology, 2024)
• A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (The New England Journal of Medicine, 2024)
• Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial (Diabetologia, 2024)
• Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis (Journal of Hepatology, 2024)
• Survodutide Once Weekly for the Treatment of Adults with Obesity (The New England Journal of Medicine, 2026)
• Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial (JACC: Heart Failure, 2024)
• Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity (Diabetes Care, 2024)
• Emerging pharmacotherapies for obesity: A systematic review (Pharmacological Reviews, 2025)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)
• GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis (World Journal of Gastroenterology, 2024)
• Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD (Alimentary Pharmacology & Therapeutics, 2025)
• Weight management treatment in obesity (Medicina Clínica, 2025)